Human medicines European public assessment report (EPAR): Tafinlar, dabrafenib, Melanoma, Date of authorisation: 26/08/2013, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Tafinlar, dabrafenib, Melanoma, Date of authorisation: 26/08/2013, Revision: 29, Status: Authorised

Allergen for therapy: Dactylis Glomerata L., Phleum Pratense L., Anthoxanthum Odoratum L., Lolium Perenne L., Poa Pratensis L.(sublingual tablet) : List of nationally authorised medicinal products - PSUSA/00010465/202212

Allergen for therapy: Dactylis Glomerata L., Phleum Pratense L., Anthoxanthum Odoratum L., Lolium Perenne L., Poa Pratensis L.(sublingual tablet) : List of nationally authorised medicinal products - PSUSA/00010465/202212

Opinion/decision on a Paediatric investigation plan (PIP): Axumin,Fluciclovine (18F), decision type: , therapeutic area: , PIP number: P/0335/2022

Opinion/decision on a Paediatric investigation plan (PIP): Axumin,Fluciclovine (18F), decision type: , therapeutic area: , PIP number: P/0335/2022

Codeine camphosulphonate / sodium benzoate, codeine camphosulphonate / sulfogaiacol / grindelia soft extract : List of nationally authorised medicinal products - PSUSA/00010542/202212

Codeine camphosulphonate / sodium benzoate, codeine camphosulphonate / sulfogaiacol / grindelia soft extract : List of nationally authorised medicinal products - PSUSA/00010542/202212

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.